Numerous approaches are being developed to promote post-natal muscle growth based on attenuating Myostatin/Activin signalling for clinical uses such as the treatment neuromuscular diseases, cancer cachexia and sarcopenia. However there have been concerns about the effects of inhibiting Activin on tissues other than skeletal muscle. We intraperitoneally injected mice with the Activin ligand trap, sActRIIB, in young, adult and a progeric mouse model. Treatment at any stage in the life of the mouse rapidly increased muscle mass. However at all stages of life the treatment decreased the weights of the testis. Not only were the testis smaller, but they contained fewer sperm compared to untreated mice. We found that the hypertrophic muscle phenotype was lost after the cessation of sActRIIB treatment but abnormal testis phenotype persisted. In summary, attenuation of Myostatin/Activin signalling inhibited testis development. Future use of molecules based on a similar mode of action to promote muscle growth should be carefully profiled for adverse side-effects on the testis. However the effectiveness of sActRIIB as a modulator of Activin function provides a possible therapeutic strategy to alleviate testicular seminoma development.
Skeletal muscle is an adaptable tissue capable of changing its mass and composition to meet the physiological needs of the human body. 1 The amount of protein present in any organ is controlled by the rate of its synthesis and breakdown and it has been estimated that, in humans, it has a turnover rate of 5.7g/kg/day, 2 with skeletal muscle proteins having an average half-life of only 20 days 3 Therefore, the regulation of skeletal muscle protein content is highly dynamic, and any failures in the mechanisms responsible may manifest in muscle loss or atrophy. A variety of clinically relevant factors have been described that lead to muscle loss including genetic mutations (e.g. Duchenne Muscular Dystrophy-DMD), diseases in non-skeletal muscles that produce muscle wasting molecules (as in cancer cachexia) and age-related muscle wasting (sarcopenia). Given that muscle wasting is such a common feature of human life, it is hardly surprising that great efforts have been made to understand muscle loss with a view of attenuating or reversing this process. Many different molecules have received interest from a therapeutic perspective over the last few decades including anabolic steroids, 4 growth hormones, 5 and IGF-1. 6 However all of these are associated with adverse side effects. The landscape of muscle growth promoting molecules was revolutionised following the discovery of Myostatin. 7 In a ground-breaking study, the group of Se-Jin Lee showed that this member of the TGF-β family of secreted signalling proteins was predominantly expressed by skeletal muscle during embryogenesis and its deletion in mouse (the Mstn -/line) led to a huge increase in muscle mass as a consequence of muscle hyperplasia and fibre hypertrophy. 7 Thereafter mutations in the Myostatin (Mstn) gene have been found in a number of mammalian species including one case in humans all of which manifest with muscle hypertrophy. 8 Thereafter a number of strategies have been developed to attenuate the activity of Myostatin during post-natal life in-order to promote muscle growth for therapeutic uses. These include: antibodies and a variety of proteins (including Follistatin, 9 GASP-1, 10 LTBP-3 11 ) that bind to Myostatin and prevent it from functioning normally, and propeptide regions that re-associate with Myostatin. 12 Alternative anti-Myostatin strategies have been developed based on ligand-receptor interactions. Myostatin and related TGF ligands such as Activin exert their action by binding to a heterotetrameric receptor complex comprised of two Type I and two Type II receptors on their target cells. Myostatin/Activin signalling is mediated by either ALK4 or ALK7 and ACVR2A or ACVR2B (henceforth ActRIIA or ActRIIB, respectively). 13 This knowledge has been exploited to develop ligand blocking antibodies to ActRIIB which have been shown to promote robust muscle hypertrophy. 14 In addition, we and others developed a stabilised peptide containing the ligand binding domain of ActRIIB (hereafter referred to as sActRIIB) which also promotes skeletal muscle growth. 15 The latter two strategies are particularly attractive in terms of muscle wasting therapies since it has been shown that Activin as well as Myostatin signal through the ActRIIB receptor to inhibit muscle growth; sActRIIB promotes muscle growth in the Mstn -/mice. 16 However studies have shown the sActRIIB binds a number of forms of Activin as well as GDF11 and BMPs 2,7, 9 and 10. [17] [18] [19] [20] The broad ligand-binding spectrum of sActRIIB raises the concern that although it is able to promote muscle growth, it may interfere with other cellular processes. Indeed, the use of a sActRIIB molecule in primates was shown to increase pancreas and spleen weights as well as interfering with glucose homeostasis. 21 In this study we examined the impact of sActRIIB on the development of the testis and sperm as both processes have been shown to be regulated by Activin. The mammalian testis is a complex organ composed of several cell types, organised in structurally distinct domains that undertake its two main functions. The seminiferous tubule is where spermatogenesis occurs and between these convoluted tubules are the interstitial cells, blood vessels and the sites of male hormone production.
Within the seminiferous tubule, surrounded by a basement membrane are Sertoli cells (SC). These are somatic cells that interact with the spermatogenic cells and act as support cells for spermatogenesis. SC proliferate and differentiate in the postnatal testis and the maximum number of SC per testis is established by day 15 in mice. Spermatogenesis is closely linked to SC function. At the basal surface of the seminiferous tubule between the SCs reside spermatogonial stem cells which gives rise to spermatogonia. Spermatogonia undergo a series of mitotic divisions that lead to spermatogonial renewal and differentiation into Type A and then Type B spermatogonia. These then undergo mitosis and differentiation to produce primary or preleptotene spermatocytes. Importantly, these diploid cells traverse through the blood-testis barrier (BTB), a tight junction between two adjacent SCs to reach the adluminal compartment. The BTB physically prevent the movement of molecules between the circulation and the adluminal compartment, isolating the adluminal compartment and sperm from the rest of the periphery. This transit is a prerequisite for the secondary or leptotene spermatocyte to enter meiotic division producing haploid round spermatids which undergo a series of differentiation steps to ultimately generate spermatozoa TGF ligand signalling is a crucial regulator of spermatogenesis. Among these factors, Activin is known to play a role at least in early stages of postnatal testicular development in mice. Evidence supports a role of Activin in determining Sertoli cell numbers and spermatogonial maturation. 22, 23 Activin expression in the testis peaks in postnatal week 1 and is diminished after the establishment of the full complement of SC numbers by the end of week 2. 24 A measurement of total Activin protein per testis however demonstrates a trough around day 20 and then increased expression from day 30 onwards. Moreover, in-situ hybridization data localises InhBA and InhBB transcripts in SC, spermatogonium as well as spermatocytes in the adult. 24 There is also evidence that Activin is produced in peritubular myoid cells. 23 These findings support a role for Activin in testicular function beyond SC number regulation in the early postnatal testis. Indeed, mice with a deletion of ActRIIA show a significant impairment of testicular growth and spermatogenesis underscoring the importance of TGF ligands that bind to this receptor in testicular development and function. 8, 25 Since the sActRIIB ligand-trap is known to bind Activin, 26 and that Activin action is crucial for testicular development and function we sought to investigate whether increase in muscle mass induced by sActRIIB is accompanied by changes in testicular biology. We have investigated whether there is a developmental window (age of mice) within which these effects are restricted and whether they are reversible over periods of nonintervention. Finally, to compare and contrast the testicular effect of inhibition of Activin or Myostatin we have also investigated the testicular phenotype of Mstn null mice. We show that sActRIIB treatment decreases testis size at any stage of the life of mice. Furthermore, we show that the testis phenotype persists longer than muscle hypertrophy following the withdrawal of sActRIIB treatment.
Materials and Methods

Ethical approval
The experiments were performed under a United Kingdom Home Office project licence, in agreement with the Animals (Scientific Procedures) Act 1986. The University of Reading Animal Care and Ethical Review Committee approved all procedures. Animals were humanely sacrificed via Schedule 1 killing.
Animal maintenance
All mice used were bred and maintained in accordance to the Animals (Scientific Procedures) Act 1986 (UK) and approved by the Biological Resources Unit of University of Reading. Post-natal Myostatin/Activin block was induced via intraperitoneal (IP) injection with 10mg/kg of sActRIIB-Fc (hereafter sActRIIB) twice weekly. The age of initial injection varied among different studies. CD1 mice were obtained from Jackson laboratories and bred for pups. 10mg/kg sActRIIB-Fc was injected at P17 until P37 in all CD1 mice studies with three collection points; P37, P56 and P180. Mstn +/and Mstn -/tissues were obtained from Versailles Saint-Quentin-en-Yvelines University at 7.5 months of age. ERCC1 ∆/mice were bred as previously described (27) with sActRIIB injections given from 7 weeks of age until 16 weeks.
Histological analysis and immunohistochemistry
Following dissection, testes were weighed and fixed in 4% PFA prior to 4°C storage. PFA fixed testis were embedded in paraffin following a series of ethanol and histoclear stages. 8µm sections were cut using a Leica RM2155 rotary microtome prior to dewaxing in Xylene. Rehydration with ethanol stages was then performed prior to antigen retrieval in 0.01M citrate buffer pH6. Blocking buffer (10% FBS in TBS-Tx) was incubated on sections for 45 minutes at room temperature prior to incubation with primary antibody overnight at 4°C. Sections were subsequently washed in PBS-Tx three times prior to incubation with secondary antibody. Secondary antibodies attached to a fluorophore were used for detection of all antibodies except PLZF and PCNA which were detected using the Vectastain ABC-HRP kit with a Vector NOVARed HRP substrate. All primary antibodies being detected were subsequently incubated with a secondary antibody for 1hour at room temperature prior to detection. Details of primary and secondary antibodies are given in Table 1 .
Haematoxylin and eosin
Teste sections were dewaxed in xylene prior to rehydration in ethanol stages. Harris heamatoxylin solution (Sigma HHS16) was then incubated on the slides for 2 minutes prior to acidic alcohol and tap water for blueing. Eosin solution (Sigma-Aldrich 318906) was 
TM4 Sertoli cell line analysis
In 24 well plate dishes approximately 70,000 TM4 cells were seeded per well. Cells were allowed to attach to the bottom of the dish for approximately 12 hours in cultured media (DMEM/F12-Gibco 11330032-supplemented with 10% FBS and 100Units/mL Penicillin 100ug/mL Streptomycin). After the 12 hours, culture media was supplemented with either 10ng/mL Activin A, 10ng/mL GDF8 or 10ng/mL GDF11. After 1 hour of supplementation, cell nuclei were stained with Nuc-Blue Life cell dye (Invitrogen) and images acquired on a Leica inverted microscope with UV filter. After 24 hour of culture cells were fixed with 4% PFA pH7.4 stained with DAPI and imaged on a Leica upright microscope. Cells were counted using the particle analysis function incorporated on public domain image analyses software Fiji. TM4 cells similarly treated for 15min were collected to prepare protein lysates as described below.
Testis Protein Lysate Preparation and Western Blotting
Frozen tissues were homogenised in detergent-free lysis buffer (50mM Tris pH 7.5, 150mM NaCl, 1mM Na3VO4, 1mM NaF, 1mM MgCl2) using a tissue grinder. These tissue lysates were then adjusted to 0.5% Triton X-100, 0.5% NP40 and incubated on ice for 15 minutes with intermittent mixing. TM4 cells were collected and directly lysed in lysis buffer as above but also containing 0.5% TritonX-100 and 0.5% NP40 and incubated on ice for 15 min with intermittent mixing. Lysates were clarified by centrifugation at 500g and protein content estimated by Bradford assay (Bio-Rad, Hercules, CA, USA). Protein western blotting was performed using standard techniques. Briefly, 100μg lysates were separated on 10% acrylamide gels and then transferred to nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ, USA). Membranes were washed in TBST (50mM Tris pH7.5, 150mM NaCl, 0.05% Tween 20) and incubated with blocking buffer (5% non-fat dry milk in TBST) at room temperature for 1 hour. Protein blots were incubated with primary antibodies, used at 1:1000 in blocking buffer, overnight at 4oC. Membranes were then washed three times with TBST and incubated with appropriate horseradish peroxidise conjugated secondary antibodies (Sigma, St. Louis, MO, USA). The membranes were again washed four times and the immunoblot was visualized by ECL (Amersham Biosciences, Piscataway, NJ, USA). Immunoreactive protein bands were analysed using the public domain Image J program. Blots were stripped and reprobed with additional antibodies using standard methods. Briefly, stripping buffer (62.5mM Tris pH6.8, 2% SDS, 100mM β-mercaptoethanol) was pre-heated to 50OC in a water bath and membranes were placed into containers containing 100ml stripping buffer and left to incubate at 50oC for 40 minutes with gentle shaking. After membranes were removed from stripping buffer, they were washed extensively in TBST. Membranes were subsequently blocked again in 5% milk block for 1 hour before additional primary antibodies were applied.
Statistical analysis
Data are presented as mean +/-SE. Significant differences between two groups were performed by the Student's t-test for independent variables. Normal distribution of data was first determined. Thereafter oneway analysis of variance followed by Bonferroni's multiple comparison tests was used for statistical differences between groups of more than two. Statistical analysis was performed on GraphPad Prism 5 with statistically significant differences considered at P<0.05.
Results
Acute impact of attenuation of Activin Receptor IIB signalling on the development of skeletal muscle and the testis
Inhibiting ligand binding to the Activin Receptor IIB has been demonstrated in a number of differing contexts to induce muscle growth in adult mice. [27] [28] [29] Here we examined the outcome of exposing very young mice. This is a period of development akin to the proposed optimum window for treating boys with DMD, to the soluble form of the Activin type IIB receptor (sActRIIB), which has been previously shown to prevent both Activin and Myostatin from binding to their receptor. Mice were injected twice weekly through the intraperitoneal route from p17 to p35 and culled at p37 (Fig. 1A) . The body weights were not significantly changed by sActRIIB treatment (Fig. 1B) . In contrast all the muscles examined had increased in weight, exemplified by the 20% increase in gastrocnemius mass (Fig. 1C ). During the course of tissue recovery, we noticed that the testis were smaller in the sActRIIB treated group compared to those receiving vehicle (PBS) (Fig. 1D ). The testis from the sActRIIB cohort were also smaller when their weight was expressed as a ratio to body weight (data not shown). We investigated the underlying cellular cause for the decreased testis weight through histological and immunocytochemical investigations. Individual seminiferous tubules were readily identifiable in both cohorts with expected peritubular, basal, adluminal cellular distribution and lumen. The tubule diameters from sActRIIB treated mice, however, were significantly smaller after sActRIIB treatment compared to controls (Fig. 1 , E and H). Lumen area was smaller in sActRIIB treated samples than those of controls but did not reach statistical significance (Fig. 1F ). Finally the area of the cellular component of each tubule was measured and revealed that this parameter was lower in sActRIIB treated samples compared to controls (Fig. 1G) . These findings suggest a reduction of spermatogenesis upon sActRIIB treatment. We then sought to elucidate whether sActRIIB treatment led to alterations in cellular distribution or processes in the testis that might cause a likely reduction in spermatogenesis.
sActRIIB treatment decreases proliferation of cells in the testis of young mice
To assess whether the reduction of seminiferous tubule cross section is caused by reduced cell proliferation we quantified the number of proliferating cell nuclear antigen (PCNA) expressing cells. While the location of proliferating cells, adjacent to the basement membrane did not differ, there were significantly fewer proliferating cells in the tubules of sActRIIB treated samples than controls (Fig. 1, I from spermatogonial stem cells (SSC) we quantified the SSC population using PLZF immunostaining, 30 and found that sActRIIB treatment did not affect spermatogonial stem cell number per tubule (Fig. 1 , J and N) or the ability of preleptotene spermatocyte to enter meiosis as demonstrated in Fig. 1 , K and O by Stra8 staining. 31 Lastly we quantified the number of Sertoli cells, identified by Sox9 expression, 32 which supports and thus ultimately limits the extent of spermatogenesis in each tubule and found no differences in this parameter between the sActRIIB treated group and controls (Fig. 1 , L and P). Importantly, at this time point we did not see evidence of sperm tails either through H -E staining or immunostaining with sperm tail specific markers, 33 including Aquaporin3 (Fig. 1H and data not shown). Of note, there was no effect on Leydig cell numbers by sActRIIB treatment (data not shown). sActRIIB decreases sperm number The data from examining the testis of p37 mice demonstrated that sActRIIB, while promoting muscle growth, prevented them from developing to their normal size. While testicular cell proliferation was reduced in mice treated with sActRIIB in the prepubertal stage, we wanted to investigate whether this affects sperm production in the adult. To that end we carried out the same experiment as outlined in Figure 1 except that mice were culled at p56 (adult) since sperm are not fully matured in mice at p37. Examination of body weights of mice treated from p17 to p35 and left for another 21 days (to p56) showed that the sActRIIB treated groups were heavier (23%) than those injected with PBS (Fig. 2, A  and B ). Although the gastrocnemius muscle in the sActRIIB group had increased in weight (by 56%), the testes were lighter (by 19%) than those of controls (Fig.  2, C and D) . Similar to the P37 mice, the cross-section of the seminiferous tubules from treated mice were smaller which was quantitatively verified to show a decrease in tubule area, lumen area and thickness of spermatogenic area in sActRIIB treated samples (Fig. 2, E-H) . Again, like the p37 experiment, the number of proliferating cells was decreased in sActRIIB samples (Fig. 2, I and N) but there was no change in the density of PLZF, Stra8 and Sox9 positive cells (Fig. 2 , I-L and O-Q). By p57, however, the control cohort contained matured spermatozoa, as evidenced by tails marked by aquaporin 3, in the seminiferous tubule lumen which was very significantly reduced in sActRIIB treated samples (Fig.  2 , M and R). We examined whether genetic background was a modifying factor in terms of tissue response to exposure to sActRIIB. We carried out a series of experiments using C57Bl10 (Fig. 3) as well as the FVB (data not shown) background. In both strains, injection of sActRIIB at p17 to p35 followed by tissue isolation at p56 (Fig. 3A ) resulted in robust muscle mass increase (Fig. 3B ) and a decrease in testis weight (Fig. 3C) . Again there was a decrease in tubule area, lumen area as well as differentiation area (Fig. 3D-F) . As for the CD1 background, immunocytochemical studies revealed a decrease in the number of PCNA and AQP3 containing tubules without any significant changes in PLZF, Stra8 or Sox9 levels ( Fig. 3G-Q) . Therefore, treatment of young mice with sActRIIB results in sustained increased skeletal muscle levels but smaller testis which (at least for the CD1 strain)
and M). Since proliferating cells, A and B type spermatogonial cells, within tubules originate
contained less than the normal number of mature spermatozoa.
sActRIIB treatment in young mice results in long term testicular abnormalities
We then investigated whether the reduced spermatogenesis in adult mice caused by a cellular proliferation defect resulting from sActRIIB treatment of pre-pubertal mice, was of a permanent nature or whether this effect was reversible. To that end we injected mice until p35 and examined tissues at p180 (Fig. 4, A-R) .
Here we failed to detect any significant difference in body, muscle or testis weight between the two cohorts. However examination of testis still showed that the sActRIIB cohort displayed lower tubule area and differentiation area compared to the PBS treated mice.
Additionally the sActRIIB cohort contained fewer spermatozoa as quantified through AQP3 staining analyses (Fig. 4, M and R) . 
sActRIIB induces testis atrophy in adult mice and in model of aged mice
The experiments conducted thus far were initiated in young mice. We next determined the consequence of sActRIIB treatment on adult mice as well as in a model of extreme ageing. In the first set of these experiments, adult mice (p56) were treated until p110 and thereafter culled at p112 (Fig. 5, A-R) . sActRIIB treated mice showed a non-significant increase in body weight but a significant increase in muscle weight compared to controls (Fig. 5, B-C) . In contrast, the testis were lighter in the sActRIIB group compared to controls (Fig. 5, D) . The sActRIIB group showed non-significant decrease in tubule area, lumen area as well as differentiation area (Fig. 5 , E-G). Nevertheless PCNA counts were lower in the sActRIIB group (Fig. 5, N) as were the number of tubules containing AQP3 positive spermatozoa (Fig. 5,  R) . Thereafter we examined the consequence of sActRIIB treatment on the ErccΔ/mice, an established mouse model of ageing. 34 Mice were injected from p56 (before signs of overt ageing) and tissues collected at p112 a time point which we have previous shown to be equivalent of over 2.5 mouse years (Fig. 6A ). 27 Progeric mice displayed lower body weights compared to controls at p112 (Fig. 6B ). sActRIIB treatment of progeric mice resulted in a non-significant increase in body weight (Fig.  6B ) accompanied by an increase in muscle mass albeit not reaching control levels (Fig. 6C) . In contrast, testis weights were lowered in ErccΔ/mice by sActRIIB (Fig.  6D ). Tubule area, lumen area as well as differentiation thickness was smaller in ErccΔ/testis compared to controls which reduced further following the treatment of ErccΔ/mice with sActRIIB ( Fig. 6 , E-G). Immunocytochemical analysis revealed crucial interplay between progeric mechanisms and inhibition of TGF signalling in the ErccΔ/mice. Whereas levels of proliferating cells, number of cells undergoing meiosis and mature spermatozoa were lower in the ErccΔ/tissue compared to controls, there was no difference between these cohorts in terms of the number of primary germ cells or Sertoli cells (Fig. 6, H-R) . Treatment of ErccΔ/mice with sActRIIB resulted in a significant decrease in PCNA and AQP3 containing tubules and a nonsignificant reduction in Sertoli cell number. Most interestingly, sActRIIB treatment lead to almost a complete downregulation of AQP3 in ErccΔ/testes resulting in a total elimination of the sperm production. These experiments show that when prepubertal mice are treated with sActRIIB, there is a strong reduction of cellular proliferation which leads to reduced spermatogenesis later in life. This treatment however does not affect the resident spermatogonial stem cell population or their ability to enter meiosis. Further, this effect is not permanent and there is a modest recovery leading to sperm production later in life. Moreover, sActRIIB treatment at any stage in the life of a mouse is likely to decreases testis size and spermatogenesis. Crucially we have also identified an interaction between TGF signalling and ageing of the testis in that sActRIIB treatment synergises with progeroid signalling to prevent germ cell entry into meiosis sActRIIB induces testicular side-effects in Myostatin null mice Our work shows that attenuation of signalling through the ActRIIB can lead to decreased testis mass. One of the molecules that promotes muscle mass through this receptor is Myostatin. To our knowledge a testicular phenotype has not been reported in Myostatin null mice but as a consequence of the results of this study, we examined both the heterozygous and null Myostatin variants. We found that both the heterozygous and homozygous Myostatin mutants had lower testis weights compared to WT litter mates ( Fig. 7, A-B ). The testis from the nulls were lighter than those from heterozygous mice but failed to reach statistical significance. Histological examination of the tissue revealed that both the heterozygous and null mice had decreased tubule, lumen and differentiation areas compared to WT litter mates ( Fig. 7 , C-F). Immunocytochemical studies revealed a decrease in the number of AQP3 containing tubules without any significant changes in PCNA, PLZF, Stra8 or Sox9 levels (Fig. 7 , G-P). Postnatal Sertoli cell numbers are regulated by FSH, IGF, testosterone, and Activin action. Since sActRIIB can inhibit Activin, Myostatin and GDF11 action, we addressed whether these ligands affect cellular proliferation in a Sertoli cell line, TM4. As shown in Fig.  8 , A, only Activin induces TM4 cellular proliferation and not Mstn or GDF11. Importantly, when investigating proximal signalling effects of these three ligands on TM4 we found only Activin to significantly induce both Smad2 and AKT activation (Fig. 8, B and C). The lack of any effect of sActRIIB treatment on Sertoli cell numbers in vivo might be due to the fact that the injection regime started at p17, and Sertoli cell proliferation is known to occur up to p15 in mice. 36 Since Myostatin does not induce Smad2 phosphorylation in TM4 cells (Fig. 8, B and C), yet show a similar phenotype as that of mice treated with sActRIIB and since sActRIIB might not traverse the blood testis barrier, it is likely that the constellation of testicular defects described in this study might be due to the reduced effect of Activin and Myostatin action on cells of the spermatogonial lineage. Crucially, however Activin inhibition appears to affect cells up to the primary spermatocytes, whereas the effect of Myostatin deletion is seen only in later stages.
Discussion
ACE-031, a molecule similar to the sActRIIB used in this study, was progressed into a phase II clinical trial on boys with DMD. However the study was stopped due to safety concerns related to epitaxis and telangiectasias. 37 Previous work has reported that a similar molecule to ACE-031 and sActRIIB used in our study induced side effects related to the spleen and pancreas. 21 In this study we hypothesised that testis development may be affected by sActRIIB given the important role that Activin has on this organ. Our study shows that sActRIIB promotes robust muscle growth in a matter of 20 days in mice. However this was accompanied by a decrease in testis weight. This effect was independent to the genetic background of mice, since here we examined three routinely used strains (CD-1, C57/Bl10 and FVB). Examination of testicular structure showed that sActRIIB inhibited the proliferation of cells in testis without impacting on the number of germ cells, undergoing meiosis or Sertoli cells. We show that following cessation of sActRIIB treatment, the rate of muscle growth in treated mice is reduced compared to untreated mice such that by 145 days after last treatment both the treated and untreated mice have the same muscle mass (Figure 4) . Importantly, although the muscle phenotype induced by sActRIIB treatment has been erased at this time, the testis phenotype has not. These results show that positive outcomes of sActRIIB treatment are shorter lived than that detrimental impact on the testis. Importantly, we show that both mature wild-type mice an ageing model undergo muscle hypertrophy and testicular atrophy following sActRIIB treatment. The most pronounced impact of the treatment in terms of potential testicular function was in fact in the model of aged mice where sActRIIB totally eliminated the formation of AQP3 positive sperm. We believe that the side effects detected after the application of sActRIIB at any stage of life is highly relevant since therapies based on attenuating Myostatin/Activin function are being developed for juvenile (e.g. DMD) 38, 39 adult (heart failure) 39 , and late onset diseases, e.g. inclusion body myostis, oculopharyngeal muscular dystrophy, 40, 41 as well as sarcopenic obesity. 42 The data from our study regarding the inhibition of testis development can be explained by on-target effects that should be expected for a molecule that inhibits Activin. 45 It is surprising that, to the best of our knowledge, a testis phenotype has not been described in other studies using similar molecules which bring about muscle growth. In many studies there is no mention that the testis were examined and even when they were, there is not data presented regarding their mass. [46] [47] It is also not clear whether testicular size was examined in boys on the ACE-083 trial. However, we suggest that in future this metric be included in any clinical trial that relies on Myostatin/Activin neutralisation as the mode of action to promote muscle growth. Although both sActRIIB treatment of wild-type mice and Myostatin deletion shows a reduction of spermatogenesis in mice, the mechanism of pathogenesis is likely to be different. Although Activin is known to play crucial local roles in both the pituitary and the ovary, sActRIIB treatment does not affect the ovarian cycle in mice (not shown) suggesting that the working of the hypothalamuspituitary-gonad (HPG) axis is intact even in the presence of a circulating inhibitor of Activin. Given this, therefore, it is not expected that sActRIIB treatment affects pituitary function in the male. Contrasting the ovary, however, testicular function of spermatogenesis is strongly affected by sActRIIB most likely due to the abrogation of Activin action on the spermatogenic cells themselves. Removal of sActRIIB treatment restores spermatogenesis supporting a partially reversible nature of this brake on the process. This reversibility is expected since sActRIIB treatment does not affect SC or germ cell numbers. Contrasting from the Mstn -/mouse testis, however, there is a clear reduction of PCNA positive cells close to the basement membrane inside the seminiferous tubule upon sActRIIB treatment. This is indicative of reduction of spermatogonial proliferation which then suggests that the reduction of testicular size and function in the injected model is due to early inhibition of spermatogenesis. The effectiveness of sActRIIB as a modulator of Activin function, demonstrated by the reduction of Smad2 activation, provides a possible therapeutic strategy to alleviate testicular seminoma development. It has been shown that when gonocyte differentiation to spermatogonia is compromised, the gonocytes produce cancer in-situ or CIS cells within the testis. 45 These cells develop into seminoma or non-seminoma origin cancers. Importantly, at every stage of the differentiation of the gonocyte to testicular cancer Smad2/3 activation appears to be a common factor. This activation might be effectively contained or inhibited by sActRIIB treatment. In addition to effects on the testis, it is likely that the ligand trap might affect Activin action elsewhere in the body in a context-dependent manner. While angiogenesis, liver and kidney function might also be affected, a pronounced behavioural effect is also expected upon sActRIIB injection. There is clear evidence of ActRIIB expression in the amygdala indicating that Activin might play a role in anxiety-type behaviour. Moreover, it is known that the presence of Activin has a calming effect on the afferents from the amygdala whereas absence or reduction of Activin can lead to aggressive behaviour stemming from heightened anxiety. In support of this, we have found that sActRIIB treated male mice show highly aggressive behaviour (not shown). Our sActRIIB injection protocol, therefore, presents a model system to further investigate behavioural issues such as anxiety and anxiety-related aggression.
Our study details an experimental intervention in mice that leads to the development of muscularity but at the same time induces testicular atrophy. A similar outcome has been described in men who abuse androgenic anabolic steroids. 53, 54 The co-presentation of these two traits in an organism are in conflict when viewed from evolutionary fitness perspective as big muscles in men are deemed indicative of high genetic quality and positive factors in mate selection by women. 55 This scenario is called the Mossman-Pacey Paradox which can be succinctly summarised as representing a conflict between masculinity and muscularity. 56 It is important to recognise that muscle mass increase induced through abuse of androgenic anabolic steroid is also associated with a list of other undesirable health issues including acne, gynaecomastia and most importantly mortality. 53 Future work will investigate these features in our mouse model of muscle growth induced by sActRIIB. Most importantly the work presented here should be taken as a warning sign for those who want to use Myostatin/Activin inhibitors for vanity purposes.
In summary, we demonstrate that attenuation of Myostatin/Activin signalling delivers significant muscle growth at any stage in the life of a rodent. However, sActRIIB injection induced an abnormal testis phenotype at any stage of the rodents life. The functional consequence of the decrease testis size may impact on fertility. Future work will investigate fertility of mice that have been treated with sActRIIB. Furthermore we will investigate in an appropriately timed manner the role this molecule plays on female reproductive organs.
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